Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target

On March 16, 2026, Jefferies downgraded Immunocore Holdings plc (NASDAQ:IMCR) to Hold from Buy antecedently with a terms people of $33, down from $48, aft assuming coverage. Jefferies has said that Immunocore Holdings plc’s (NASDAQ:IMCR) pb merchandise Kimmtrak addresses a “moderate” full addressable marketplace successful uveal melanoma and is nearing highest sales, adding that further upside present depends connected pipeline success, wherever “shots connected extremity look risky.”

Last month, Immunocore Holdings plc (NASDAQ:IMCR) reported fourth-quarter EPS of (60c), beneath the (20c) statement estimate. Revenue came successful astatine $104.5M compared with the $107.77M consensus. Chief Executive Officer Bahija Jallal has said that Immunocore Holdings plc (NASDAQ:IMCR) delivered “a productive twelvemonth of maturation and progress” successful 2025, supported by $400M successful Kimmtrak income and continued pipeline development. Bahija Jallal has added that 2026 volition absorption connected executing objective trials, with cardinal information expected successful oncology and the commencement of its archetypal autoimmune study.

15 States with the Best Healthcare successful the US

Immunocore Holdings plc (NASDAQ:IMCR) develops and commercializes immunomodulating therapies targeting cancer, infectious diseases, and autoimmune conditions.

While we admit the imaginable of IMCR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.